Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated
Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tum...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 7, 2021
|
| In: |
Journal of clinical oncology
Year: 2021, Volume: 39, Issue: 34, Pages: 3839-3852 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.21.00784 |
| Online Access: | Resolving-System, kostenfrei: https://doi.org/10.1200/JCO.21.00784 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.21.00784 |
| Author Notes: | Sybren L.N. Maas, Damian Stichel, Thomas Hielscher, Philipp Sievers, Anna S. Berghoff, Daniel Schrimpf, Martin Sill, Philipp Euskirchen, Christina Blume, Areeba Patel, Helin Dogan, David Reuss, Hildegard Dohmen, Marco Stein, Annekathrin Reinhardt, Abigail K. Suwala, Annika K. Wefers, Peter Baumgarten, Franz Ricklefs, Elisabeth J. Rushing, Melanie Bewerunge-Hudler, Ralf Ketter, Jens Schittenhelm, Zane Jaunmuktane, Severina Leu, Fay E.A. Greenway, Leslie R. Bridges, Timothy Jones, Conor Grady, Jonathan Serrano, John Golfinos, Chandra Sen, Christian Mawrin, Christine Jungk, Daniel Hänggi, Manfred Westphal, Katrin Lamszus, Nima Etminan, Gerhard Jungwirth, Christel Herold-Mende, Andreas Unterberg, Patrick N. Harter, Hans-Georg Wirsching, Marian C. Neidert, Miriam Ratliff, Michael Platten, Matija Snuderl, Kenneth D. Aldape, Sebastian Brandner, Jürgen Hench, Stephan Frank, Stefan M. Pfister, David T.W. Jones, Guido Reifenberger, Till Acker, Wolfgang Wick, Michael Weller, Matthias Preusser, Andreas von Deimling, and Felix Sahm |
| Summary: | Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established (CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma. |
|---|---|
| Item Description: | Gesehen am 20.10.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.21.00784 |